Friday, 16 October 2026European Markets

CROSSWOOD Stock Is 28% Up In The Last 21 Sessions

Loading stream...

as the world of stock market undergoes various fluctuations, one of the most distinct rises belongs to crosswood (cros.pa) stocks on the cac 40. these stocks have shown an impressive surge of 28.14% over just 21 sessions – increasing from eur8.35 to eur10.70! significantly, this positive swing was observed after five back-to-back sessions of declines, marking a major turn in their trajectory.

crosswood vs cac 40 index

the growth of crosswood shares brought forth an interesting contrast when compared with the movements of the cac 40 index. this index only recorded a modest gain of 0.07% at eur7,265.70 on friday, after being on a three-day decline.

crosswood's room for recovery

despite its recent show of strength, crosswood still stands 38.86% below its 52-week high that was at eur17.50, indicating there's still a significant margin for recovery.

about crosswood sa

crosswood sa, originally known as desquenne et giral from france, takes pride in an expansive property portfolio that covers shops, offices, and housing units. the operations are conducted through their subsidiary, compagnie financiere de broceliande.

earnings per share and potential profitability

the company's trailing 12-month earnings per share (eps) was reported to be eur0.57. this value is derived from the earnings for the trailing 12-month period that ended on 31 october 2013. the eps graph is a significant parameter in shares as it suggests the amount of a company's profit is being allocated to each unit of its common stocks; the higher figures usually point toward more profitability for the organization.

analysis of crosswood's price earnings ratio

a closer look at the price earnings ratio of crosswood stock discloses a pe ratio of 18.77. this ratio indicates that the investors are ready to pay eur18.77 for every euro earned each year - even after recent losses. this calculation suggests that the market participants hold high expectations for this stock, despite the recent downturn.

more news about crosswood (cros.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com